IMMUNITYBIO, INC. Deferred Income Tax Liabilities, Net
IMMUNITYBIO, INC. (IBRX) had Deferred Income Tax Liabilities, Net of $162.00 thousand as of 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2022-08-08
- 2022-06-30: Deferred Income Tax Liabilities, Net $162.00K.
- 2022-03-31: Deferred Income Tax Liabilities, Net $162.00K.
- 2021-12-31: Deferred Income Tax Liabilities, Net $162.00K.
- 2021-09-30: Deferred Income Tax Liabilities, Net $170.00K.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2022-06-30 | $162.00K 10-Q · filed 2022-08-08 |
| 2022-03-31 | $162.00K 10-Q · filed 2022-05-10 |
| 2021-12-31 | $162.00K 10-Q · filed 2022-08-08 |
| 2021-09-30 | $170.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $170.00K 10-Q · filed 2021-08-12 |
| 2021-03-31 | $170.00K 10-Q · filed 2021-05-14 |
| 2020-12-31 | $170.00K 10-K · filed 2022-03-01 |
| 2019-12-31 | $3.11M 8-K/A · filed 2021-04-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |